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Identification of Novel FAM134B 
(JK1) Mutations in Oesophageal 
Squamous Cell Carcinoma
Md. Hakimul Haque1,*, Vinod Gopalan1,*, Kwok-wah Chan2, Muhammad J. A. Shiddiky3, 
Robert Anthony Smith1,4 & Alfred King-yin Lam1,*
Mutation of FAM134B (Family with Sequence Similarity 134, Member B) leading to loss of function of 
its encoded Golgi protein and has been reported induce apoptosis in neurological disorders. FAM134B 
mutation is still unexplored in cancer. Herein, we studied the DNA copy number variation and novel 
mutation sites of FAM134B in a large cohort of freshly collected oesophageal squamous cell carcinoma 
(ESCC) tissue samples. In ESCC tissues, 37% (38/102) showed increased FAM134B DNA copies whereas 
35% (36/102) showed loss of FAM134B copies relative to matched non-cancer tissues. Novel mutations 
were detected in exons 4, 5, 7, 9 as well as introns 2, 4-8 of FAM134B via HRM (High-Resolution Melt) 
and Sanger sequencing analysis. Overall, thirty-seven FAM134B mutations were noted in which 
most (31/37) mutations were homozygous. FAM134B mutations were detected in all the cases with 
metastatic ESCC in the lymph node tested and in 14% (8/57) of the primary ESCC. Genetic alteration of 
FAM134B is a frequent event in the progression of ESCCs. These findings imply that mutation might be 
the major driving source of FAM134B genetic modulation in ESCCs.
Oesophageal squamous cell carcinoma (ESCC) is the most common histological subtype of oesophageal carcino-
mas and it has complex molecular pathology compared to other carcinomas1–3. Identification of various genetic 
and epigenetic changes including mutations of key regulatory genes have a significant role in predicting the bio-
logical behaviour of ESCC as well as the prognosis of the patients with ESCC4–13.
Our previous studies using comparative genomic hybridization analysis revealed that genes in the region of 
chromosome 5p play a vital role in the pathogenesis of ESCC14,15. FAM134B (Family with sequence similarity 134, 
member B) also known as JK1is a novel gene placed at chromosome 5p15.1 downstream of δ -catenin16. The onco-
genic properties of FAM134B (JK1) were first reported both in ESCC tissues and cell lines, while ESCC tissues 
also showed altered FAM134B expression16. Also, our recent studies have confirmed the growth related properties 
of FAM134B by exhibiting multiple tumour suppressor properties of FAM134B (JK1) in colorectal cancer tissues 
and cell lines17–19.
Recently, other researchers have reported that FAM134B encodes a cis-Golgi transmembrane protein, and its 
mutation can regulate cell apoptosis and long-term survival of nociceptive and autonomic ganglion neurons20–25. 
Homozygous loss of function mutations in FAM134B was reported for the first time in hereditary sensory and 
autonomic neuropathy type IIB (HSAN IIB) and in vascular dementia20,24. In addition, Khaminets et al. have 
most recently noted that FAM134B regulated endoplasmic reticulum turnover by selective autophagy25. To the 
best of our knowledge, at the time of writing, there is no data available on the mutational significance of FAM134B 
in human cancers. Also, the clinicopathological correlation of FAM134B mutation and clinicopathological 
parameters has never been reported in human cancer samples. Thus, the current study aims to detect mutations 
in different exon and intron regions of FAM134B (JK1) in ESCC tissue samples. In addition, the correlations of 
FAM134B (JK1) mutations with various clinicopathological parameters and natural copy number variations in 
ESCCs were analysed.
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Results
Identification of FAM134B (JK1) DNA in ESCC tissues. FAM134B (JK1) DNA was identified in all the 
studied samples. In these samples, 600-base pairs (bp), 281-bp, 259-bp, 329-bp, 282-bp, 346-bp, 256-bp, 314-bp 
and 106-bp fragments were amplified for exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8 and exon 
9 of FAM134B (JK1) respectively. Also, a 225-bp fragment was amplified for the control gene, haemoglobin delta 
(HBD) (Fig. 1a,b).
FAM134B (JK1) copy number variations. In ESCC (n = 102), 37% (n = 38) showed increased FAM134B 
(JK1) copies whereas 35% (n = 36) showed a loss of FAM134B (JK1) copies relative to matched non-cancer tissue. 
Meanwhile, the remaining 22% (n = 28) did not show any change in copies. In ESCCs with lymph node metastasis 
(n = 64), 66% (n = 42) showed high FAM134B (JK1) copies whereas 34% (n = 22) revealed deletion (p = 0.80). 
The DNA copy number of FAM134B (JK1) in cancer showed no statistical correlations with the grades and patho-
logical stages of ESCC or with the gender and the age of the patient (p > 0.05) (Table 1).
Mutation screening using high-resolution Melt (HRM) curve and Sanger sequencing. FAM134B 
(JK1) mutations showed no correlation with other clinical and pathological features of ESCC including gender, 
age of the patient as well as the sites, histological grades and pathological stages of carcinoma (p > 0.05) (Table 2). 
Also, mutations did not show any correlation with the DNA copy number of FAM134B (JK1) (Tables 3 and 4).
Overall, 37 FAM134B (JK1) mutations were found in ESCC (Tables 3 and 4). Of these, 36 FAM134B (JK1) 
mutations were noted in metastatic ESCC in lymph node and 16 mutations were detected in primary cancer. Of 
these 37 mutations, 6 were heterozygous mutations and 31 were homozygous mutations. On the other hand, only 
14% (8/57) of the primary carcinoma harboured mutations of FAM134B (JK1). Mutations were noted in both 
the primary cancer and the lymph node metastasis with ESCC in 2 cases. In these 2 cases (cases 43 and 50), the 
mutations noted were identical. Also, of the 37 FAM134B (JK1) mutations, 11 mutations result in alteration of the 
amino acid sequences in FAM134B (JK1) protein while 26 mutations were synonymous.
Among the 9 exons of FAM134B (JK1) examined, mutations were detected in exons 4, 5, 7 and 9 as well as 
introns 2, 4, 5, 6, 7 and 8 for FAM134B (JK1) in ESCC (Figs 2 and 3). In exon 9 of FAM134B (JK1), thirteen sub-
stitution and one frameshift (deletion) mutations were documented in ESCCs. The most common substitution 
variants in exon 9 are c. 1129T > C, c. 1107G > C, c. 1112T > C which alters the codons and subsequently amino 
acids - TCA > CCA (p. Ser348Pro), GAG > GAC (p. Glu340Asp) and GTT > GCT (p. Val342Ala) respectively. 
One frameshift (deletion) FAM134B (JK1) mutation, c. 1137delT, which alters the codon TTT > TTC resulting in 
no change in amino acid, but altered amino acids following the frameshift (p. Phe379fs) was noted in ESCC. For 
exon 4 of FAM134B (JK1), two mutations, c. 546-547CT > GG and c. 660G > A, were detected in ESCC tissues 
(Table 3). The mutation in c. 546-547CT > GG change the codons in amino acids - AGC > AGG (p. Ser153Arg) 
and TGG > GGG (p. Trp154Gly). Meanwhile the mutation in c. 660G > A change the codons in amino acids- 
GAA > AAA (p. Glu163Lys). Furthermore, four polymorphisms were in identified intron 4 FAM134B (JK1) in 
ESCC.
Mutations in other exons and introns of FAM134B (JK1) were less common in ESCC. There was no mutation 
noted in exon 8 of FAM134B (JK1) in ESCC. However, two types of variants, c961-33delA and c1087 + 97C > A, 
Figure 1. FAM134B (JK1) gene amplification in oesophageal squamous cell carcinoma. (a) Amplified 
PCR products of FAM134B (JK1) (122bp) and HBD (225bp) in 2% agarose gel. FAM134B (JK1) and HBD 
were present in all the samples (2–14) except for the water control (15). Fifty-base pair DNA ladder was used 
for comparison. (b) Representative amplified PCR products of exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, 
exon 7, exon 8 and exon 9 of FAM134B (JK1) in 1.5% agarose gel. Hundred-base pair DNA ladder was used for 
comparison.
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were detected in intron 8. Also, one silent mutation (c. 816C > T) and a mutation (c. 873 + 23T > C) were 
noted for exon 7 and intron 7 of FAM134B (JK1) in ESCC respectively. In addition, two synonymous variants 
(c. 319G > A and c. 352C > T) were noted in exon 5 of FAM134B in ESCC. Lastly, five polymorphisms were 
detected in intron 2 of FAM134B (with the most frequent variant being c. 408-27delA).
Discussion
Chromosomal copy number changes can indicate activation of oncogenes and inactivation of tumour suppressor 
genes in human cancers26. In our previous studies, FAM134B (JK1) copy number alterations were found as a fre-
quent event in colorectal adenoma and adenocarcinoma19. The current study is the first to investigate FAM134B 
(JK1) copy number changes in a large cohort of ESCC. Approximately one third of cancers studied revealed 
amplification and one third revealed deletion of FAM134B in ESCC. This altered DNA copy number changes of 
FAM134B indicate its varied modulation potential in different ESCC patients.
This current study is the first systematic study to investigate mutation sites in FAM134B (JK1) gene in ESCC. 
Until now, five homozygous mutations of FAM134B (JK1) were detected in neurological diseases. They are three 
nonsense mutations, one frame-shift mutation, and one is a splice-site mutation20–23. These mutations were 
located in exon 1 and intron 7 of the gene. In addition, there were 2 heterozygous mutations reported in exon 1. In 
ESCC, we have noted 37 distinct mutations of FAM134B (JK1). Thirty-one are homozygous mutations and 6 were 
heterozygous mutations. These mutations were found in exons 4, 5, 7, 9 and introns 2, 4, 5, 6, 7 and 8 of FAM134B 
(JK1). None of these mutation sites are identical to those noted reported in the neurological diseases. Thus, the 
mutations related to the pathogenesis of ESCC appear to be are unique. The roles of FAM134B (JK1) mutations in 
the pathogenesis of the cancer should therefore be different from their roles in neurological diseases. The mech-
anisms and presence of any downstream effects of the FAM134B (JK1) mutations need to be further investigated 
in ESCC to confirm their significance.
Of the 37 novel mutation sites in FAM134B (JK1) detected in ESCC, 11 mutations changed the amino acid of 
the resulting protein while 26 mutation sites do not alter the amino acid composition of the protein. The most 
common mutations are present in exon 9. Amongst the 11 mutations that changed the amino acid structure of JK1 
are three relatively common variants in exon 9 (c. 1129T > C, c. 1107G > C, c. 1112T > C). Of these, c. 1129T > C, 
Characteristics
Number of 
Patients
DNA copy
P valueAmplification Deletion No change
Age
 < 60 years 34(33.3%) 15(44.1%) 7(20.6%) 12(35.3%) 0.07
 > 60 68(66.7%) 23(33.8%) 29(42.6%) 16(23.5%)
Gender
 Male 84(82.4%) 32(38.1%) 28(33.3%) 24(28.6%) 0.66
 Female 18(17.6%) 6(33.3%) 8(44.4%) 4(22.2%)
Histological Grade
 Well 22(21.6%) 10(45.5%) 6(27.3%) 6(27.3%) 0.61
 Moderate 59(57.8%) 23(39.0%) 21(35.6%) 15(25.4%)
 Poor 21(20.6%) 5(23.8%) 9(42.9%) 7(33.3%)
Site
 Upper 12(11.8%) 5(41.7%) 6(50.0%) 1(8.3%) 0.12
 Middle 55(53.9%) 23(41.8%) 14(25.5%) 18(32.7%)
 Lower 35(34.3%) 10(28.6%) 16(45.7%) 9(25.7%)
T Stage
 1 6(5.9%) 2(33.3%) 2(33.3%) 2(33.3%) 0.85
 2 11(10.8%) 5(45.5%) 5(45.5%) 1(9.1%)
 3 64(62.7%) 23(35.9%) 22(34.4%) 19(29.7%)
 4 21(20.6%) 8(38.1%) 7(33.3%) 6(28.6%)
Lymph node Metastasis
 Negative 38(37.3%) 11(28.9%) 14(36.8%) 13(34.2%) 0.33
 Positive 64(62.7%) 27(42.2%) 22(34.4%) 15(23.4%)
Distant metastasis
 Negative 97(95.1%) 35(36.1%) 35(36.1%) 27(27.8%) 0.55
 Positive 5(4.9%) 3(60.0%) 1(20.0%) 1(20.0%)
TNM Stage
 Stage I 6(5.9%) 4(66.7%) 0(0.0%) 2(33.3%) 0.22
 Stage II 26(25.5%) 7(26.9%) 12(46.2%) 7(26.9%)
 Stage III 65(63.7%) 24(36.9%) 23(35.4%) 18(27.7%)
 Stage IV 5(4.9%) 3(60.0%) 1(20.0%) 1(20.0%)
Table 1.  Clinicopathological features of ESCC and JK1 (FAM134B) copy number variation.
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is predicted by in silico methods as being of minimal effect due to lack of conservation of this amino acid in other 
species while the other two have potentially higher functional significance due to their predicted ability to also 
cause splice site modification in the protein. In addition, in exon 9 of FAM134B (JK1), one frame-shift (deletion) 
mutation, c. 1137delT, is likely to have increased functional significance as it radically alters and can truncate the 
protein as well as potentially changing exon splicing of the RNA. The other important mutation that lead to an 
amino acid change was noted in exon 4 resulting in an exon change GAA > AAA (protein change-p.Glu163Lys). 
The novel mutations detected in this study that alters the amino acid structure of FAM134B (JK1) have potential 
to affect the function of FAM134B (JK1).
In the current study, FAM134B (JK1) mutations were noted predominately in metastatic ESCCs present in 
lymph nodes, implying that they have a role in the pathogenesis of lymph node metastases in ESCC. Mutation in 
the majority of metastatic lymph node tissues compared to primary tumours (Table 3) indicates that FAM134B 
(JK1) mutation may offer a survival advantage in different tumour microenvironments, or assist in colonisation 
of those particular microenvironments. Differing FAM134B (JK1) sequences imply that, the molecular interac-
tions and characteristics would differ between primary and metastatic tumours. Furthermore, the classical model 
for metastatic processes suggests that the majority of the cancer cells in the primary tumour have low metastatic 
potential and only a few cells acquire enough somatic mutations to become metastatic27. Thus, the absence of 
FAM134 (JK1) mutation in the bulk of primary ESCC tissues in this study might be due to the harvesting of can-
cer cells with fewer somatic mutations. Hence, it can be hypothesised that FAM134B (JK1) might act as a poten-
tial target for predicting lymph node metastasis in ESCC patients. Further research with a larger series of ESCC 
patients with matched metastatic tissues and potentially functional studies on particular mutations are needed to 
confirm the metastatic potential of FAM134B (JK1).
In conclusion, we identified for the first time the mutation of FAM134B (JK1) in ESCC tissue samples. The 
altered expression patterns and copy number variations of FAM134B in ESCCs might be modulated by these 
mutation changes in FAM134B. In this study, FAM134B mutations were frequently observed in metastatic 
lymph node tissues indicating its use as a potential predictor for metastasis in ESCCs. Multiple different genetic 
Characteristics
Number of 
patients
Mutation 
cases
No 
mutation 
cases p value
Age
 < 60 year 20 11 9 0.17
 > 60 year 37 13 24
Gender
 Male 50 19 31 0.12
 Female 7 5 2
Site
 Upper 5 2 3 0.44
 Middle 40 15 25
 Lower 12 7 5
Grade
 Well 20 7 13 0.58
 Moderate 28 12 16
 Poor 9 5 4
T Stage
 1 1 0 1 0.62
 2 6 3 3
 3 38 17 21
 4 12 4 8
Lymph node Metastasis
 Negative 20 7 13 0.58
 Positive 37 17 20
Distant metastasis
 Negative 54 22 32 0.57
 Positive 3 2 1
TNM Stage
 Stage I 1 1 0 0.55
 Stage II 14 5 9
 Stage III 39 17 22
 Stage IV 3 2 1
Table 2.  Clinicopathological features and JK1 (FAM134B) mutations in oesophageal squamous cell 
carcinoma.
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Exons
Sample 
Code
Primary 
cancer with 
mutation
Lymph node 
metastasis 
with mutation
FAM134B DNA copy 
number change
DNA change
Type of 
mutation Codon change Protein change Comments
Primary 
cancer
Lymph node 
metastasis
 Exon 9 
41 No Yes N N c. 1128T > A Substitution CTT > CTA p.Leu347Leu Potentially functional due to splice site modification
30 No Yes D D c. 1107G > C c. 1129T > C Substitution GAG > GAC TCA > CCA
p.Glu340Asp 
p.Ser348Pro
pGlu340Asp - Likely 
functional significance 
pSer348Pro - 
Probably lesser effect/
polymorphism due to 
lack of conservation in 
other species
14 Yes No A A c. 1149A > G Substitution GAA > GAG p.Glu354Glu
Likely functional 
significance (also affects 
splice sites)
19 No Yes D A c. 1112T > C c. 1129T > C Substitution GTT > GCT TCA > CCA
p.Val342Ala 
p.Ser348Pro
pVal342Ala - Likely 
functional significance 
(also affects splice 
sites) pSer348Pro - 
Probably lesser effect/
polymorphism due to 
lack of conservation in 
other species
3 Yes No D D c. 1112T > C c. 1149A > G c. 1152T > G c. 1153G > C  Substitution
GTT > GCT 
GAA > GAG 
AAT > AAG 
GGC > CGC
p.Val342Ala 
p.Glu354Glu 
p.Asn355Lys 
p.Gly356Arg
pVal342Ala - Likely 
functional significance 
(also affects splice sites) 
pGlu354Glu - Likely 
functional significance 
(also affects splice sites) 
pAsn355Lys - Likely 
functional significance 
pGly356Arg - Likely 
functional significance 
(also affects splice sites)
35 Yes No A –
c. 1092T > G c. 1093G > C c. 
1097GA > AC c. 1107G > T 
c. 1129T > C
 Substitution 
CTT > CTG 
GAC > CAC 
CGA > CAC 
GAG > GAC 
TCA > CCA
p.Leu335Leu 
p.Asp336His 
p.Arg337His 
p.Glu340Asp 
p.Ser348Pro
pLeu335Leu - Likely 
functional significance 
(also affects splice sites) 
pAsp336His- Likely 
functional significance 
(also affects splice sites) 
pArg337His - Likely 
functional significance 
(also affects splice 
sites) pGlu340Asp 
- Likely functional 
significance pSer348Pro 
- Probably lesser effect/
polymorphism due to 
lack of conservation in 
other species
43 Yes Yes A N c. 1112T > C c. 1129T > C c. 1092T > G c. 1093G > C Substitution
GTT > GCT 
TCA > CCA 
CTT > CTG 
GAC > CAC
p.Val342Ala 
p.Ser348Pro 
p.Leu335Leu 
p.Asp336His
pVal342Ala - Likely 
functional significance 
(also affects splice 
sites) pSer348Pro - 
Probably lesser effect/
polymorphism due to 
lack of conservation in 
other species pLeu335Leu 
- Likely functional 
significance (also affects 
splice sites) pAsp336His- 
Likely functional 
significance (also affects 
splice sites)
47 Yes No D – c. 1107G > C c. 1129T > C Substitution GAG > GAC TCA > CCA
p.Glu340Asp 
p.Ser348Pro
pGlu340Asp - Likely 
functional significance 
pSer348Pro - 
Probably lesser effect/
polymorphism due to 
lack of conservation in 
other species
50 Yes Yes D A c. 1107G > T c. 1129T > C c. 1164A > G  Substitution 
GAG > GAC 
TCA > CCA 
ACA > ACG
p.Glu340Asp 
p.Ser348Pro 
p.Thr360Thr
pGlu340Asp - Likely 
functional significance 
pSer348Pro - 
Probably lesser effect/
polymorphism due to 
lack of conservation in 
other species pThr360Thr 
-Likely functional 
significance (also affects 
splice sites)
Continued
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alterations incorporating mutations in coding sequences of FAM134B were observed and each might entail either 
alterations to expression or functional changes of this gene that could play a fundamental role in the progression 
of ESCCs.
Methods
Recruitment of tissue samples and clinicopathological data. Matched tumour samples and 
non-cancer tissue (near the surgical resection margin) from the same patient who underwent resection of ESCC 
were prospectively collected, snapped frozen in liquid nitrogen and stored in minus 80 °C by the author (AKL). 
Informed consent was obtained from all subjects. In addition, in each case, macroscopically enlarged lymph 
nodes suspicious for lymph node metastasis were also sampled, snap frozen and stored. After the collection, 
additional tissues blocks were taken, fixed in formalin and embedded in paraffin for pathological examination. 
Sections were then cut from these blocks and haematoxylin and eosin stained. They were studied by the author 
(AKL). The ESCCs were graded according to the World Health Organization (WHO) criteria27. The carcinomas 
Exons
Sample 
Code
Primary 
cancer with 
mutation
Lymph node 
metastasis 
with mutation
FAM134B DNA copy 
number change
DNA change
Type of 
mutation Codon change Protein change Comments
Primary 
cancer
Lymph node 
metastasis
51 Yes No N – c. 1112T > C c. 1129T > C Substitution GTT > GCT TCA > CCA
p.Val342Ala 
p.Ser348Pro
pVal342Ala - Likely 
functional significance 
(also affects splice 
sites) pSer348Pro - 
Probably lesser effect/
polymorphism due to 
lack of conservation in 
other species 
34 Yes No A – c. 1137delT Deletion TTT > TTC p.Phe350Phe
pPhe350Phe- Likely 
functional significance 
(frameshift mutation, 
truncates protein, may 
change splicing)
 Exon 7
39 No Yes A N c. 816C > T or c. 903C > T Substitution GAT > GAC p.Asp272Asp
pAsp272Asp-Likely 
functional significance 
(also affects splice sites)
19 No Yes D A c. 816C > T or c. 903C > T Substitution GAT > GAC p.Asp272Asp
pAsp272Asp -Likely 
functional significance 
(also affects splice sites)
 Exon 5 
14 Yes No A A c. 711G > Ac. 744C > T Substitution Substitution
ACG > ACA 
CTC > CTT
p.Thr208Thr 
p.Leu219Leu
Has no functional 
significance Has no 
functional significance
6 No Yes A A c. 711G > A Substitution ACG > ACA p.Thr208Thr Has no functional significance
12 No Yes N N c. 711G > A Substitution ACG > ACA p.Thr208Thr Has no functional significance
41 No Yes N N c. 711G > A Substitution ACG > ACA p.Thr208Thr Has no functional significance
20 No Yes N N c. 711G > A Substitution ACG > ACA p.Thr208Thr Has no functional significance
11 No Yes A N c. 711G > A Substitution ACG > ACA p.Thr208Thr Has no functional significance
3 Yes No D D c. 711G > A Substitution ACG > ACA p.Thr208Thr Has no functional significance
15 No Yes D N c. 711G > A Substitution ACG > ACA p.Thr208Thr Has no functional significance
 Exon 4
6 No Yes A A c. 546–547CT > GG c. 660G > A
Substitution 
Substitution
AGC > AGG 
and 
TGG > GGG 
GAA > AAA
p.Ser153Arg 
p.Trp154Gly 
p.Glu163Lys
pSer153Arg and 
pTrp154Gly-Likely 
functional significance. 
(also affects splice sites) 
pGlu163Lys-Likely 
functional significance 
(also affects splice sites).
38 No Yes N D c. 660G > A Substitution GAA > AAA p.Glu163Lys
pGlu163Lys-Likely 
functional significance 
(also affects splice sites).
30 No Yes D D c. 660G > A Substitution GAA > AAA p.Glu163Lys
pGlu163Lys-Likely 
functional significance 
(also affects splice sites).
43 No Yes A N c. 660G > A Substitution GAA > AAA p.Glu163Lys
pGlu163Lys-Likely 
functional significance 
(also affects splice sites).
59 No Yes N D c. 660G > A Substitution GAA > AAA p.Glu163Lys
pGlu163Lys-Likely 
functional significance 
(also affects splice sites).
19 No Yes D A c. 660G > A Substitution GAA > AAA p.Glu163Lys
pGlu163Lys-Likely 
functional significance 
(also affects splice sites).
Table 3.  Mutations detected in different exons of FAM134B (JK1) in ESCC.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:29173 | DOI: 10.1038/srep29173
were staged as per the TNM (tumour, lymph node and metastases) classification adopted in the American Joint 
Committee on Cancer28. Overall, tissues from 102 patients with ESCC were recruited. Eighteen patients had 
lymph nodes with metastatic ESCC sampled. For each patient, clinical and pathological parameters including 
gender and age of patients as well as the sites, grades, pathological stages of the ESCC were recorded.
Genomic DNA extraction. Ethical approval was obtained for the use of these samples (GU Ref No: 
MED/19/08/HREC) by the Griffith University human research ethics committee. The methods were carried out 
in accordance with the approved guidelines. .
The selected samples were sectioned using a cryostat (Leica CM 1850 UV, Wetzlar, Germany) and stained by 
haematoxylin and eosin. Light microscopic examination was performed by author, AKL, to confirm the presence 
of non-cancer and cancerous tissues for genomic DNA extraction. Five 10 μ m slices was sectioned from the fro-
zen tissue samples for DNA extraction. DNA was extracted and purified from frozen tissue samples using all prep 
DNA/RNA mini kit (Qiagen, Hilder, Germany), following manufacturer’s instructions. DNA quantification was 
accomplished via Nanodrop Spectrophotometer (BioLab, Ipswich, MA, USA) and purity was measured using 
260/280 ratio. Concentration of DNA was noted in ng/μ l and then stored at − 20 °C until use.
Introns
Sample 
Code
Primary 
cancer
Lymph node 
metastasis
FAM134B DNA copy 
number change
DNA change Type of mutation
Primary 
cancer
Lymph node 
metastasis
Intron 2
39 No Yes A N c. 514 + 144delA c. 514 + 37 − 38delTT Deletion Deletion
41 No Yes N N c. 408 − 27delA c. 514 + 37 − 38delTT Deletion Deletion
20 No Yes N N
c. 408 − 27delA c. 
514 + 34T > A c. 
514 + 37 − 38delTT
Deletion Substitution 
Deletion
73 No Yes A A c. 408 − 27delA Deletion
 Intron 4
16 No Yes N D c. 408 − 27delA c. 514 + 37 − 38delTT Deletion Deletion
39 No Yes A N c. 546 − 64delA c. 672 + 46 − 47delTG Deletion Deletion
6 No Yes A A
c. 546 − 64delA 
c. 546 − 56delA c. 
672 + 46 − 47delTG
Deletion Deletion Deletion
38 No Yes N D c. 546 − 56delA c. 672 + 26delT Deletion Deletion
30 No Yes D D c. 546 − 64delA c. 546 − 56delA Deletion Deletion
Intron 5
43 No Yes A N c. 546 − 56delA c. 672 + 26delT Deletion Deletion 
59 No Yes N D
c. 546 − 56delA 
c. 672 + 26delT c. 
672 + 46 − 47delTG
Deletion Deletion Deletion
19 No Yes D A c. 546 − 56delA Deletion
41 No Yes N N c. 673 − 54delC Deletion
11 No Yes A N c. 673 − 54C > A c. 757 + 56G > A Substitution Substitution
3 Yes No D D c. 673 − 65delA Deletion
15 No Yes D N c. 757 + 56G > A c. 673 − 52 − 53GA > AG Substitution Substitution
Intron 6
38 No Yes N D c. 758 − 61 − 62TG > CTc. 758 − 71G > T Substitution Substitution
30 No Yes D D c. 758 − 71G > T Substitution
 Intron 7 19 No Yes D A c. 873 + 23T > C or c. 960 + 23T > C Substitution
Intron 8
14 Yes No A A c. 1087 + 97C > A Substitution
6 No Yes A A c. 1087 + 97C > A Substitution
30 No Yes D D c. 961 − 33delA c. 1087 + 97C > A Deletion Substitution
41 No Yes N N c. 961 − 33delA c. 1087 + 97C > A Deletion Substitution
31 No Yes A A c. 961 − 33delA c. 1087 + 97C > A Deletion Substitution
Table 4.  Mutations detected in different introns of FAM134B (JK1) in ESCC.
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Primer design. Primers specific for determining FAM134B mutation and copy number changes were 
designed based on GenBank accession number for variant 1 NM_001034850 and for variant 2 NM_019000 as well 
as for a control gene, HBD (GenBank accession number NM_000519) using Primer3 version 0.4.0 (http://frodo.
wi.mit.edu/primer3). All primers were analysed for specificity using Primer Blast (http://www.ncbi.nlm.nih.gov/
tools/primer-blast) and Primer Premier program version 5 (Premier Biosoft, Palo Alto, CA, USA) to check for 
primer parameters like GC content, annealing temperature of primer and Δ G (Gibbs free energy change - energy 
required to break the secondary structure) and to forecast any possible mismatching, primer dimmer or hairpin 
formation.
Figure 2. Validation of FAM134B (JK1) different exons sequence variant HRM curve analysis results by 
Sanger sequencing. (a) The presence of variant (GAA > AAA) in exon 4 of FAM134B (JK1) is demonstrated 
via normalized melting curves and sequencing (mutant versus wildtype). (b) HRM analysis shows the 
polymorphism (GAT > AAT) in exon 5 of FAM134B (JK1) as evident by normalized melting curves and 
sequencing (mutant versus wide type). (c) The presence of variant (AAT > AAC) in exon 7 of FAM134B (JK1) 
is confirmed via normalized melting curves and sequencing (mutant versus wide type). (d) The evidence of 
mutant (AAA > AGA) in exon 9 of FAM134B (JK1) is showed using normalized melting curves and sequencing 
(mutant versus wide type).
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Primers for FAM134B (JK1) gene were designed within the intronic regions on either side of the exon of 
interest to ensure coverage of the entire exon 1 to exon 9 to amplify and direct sequencing both isoforms of the 
gene for screening of mutations in ESCC. Primers were also designed for FAM134B (JK1) and control gene - hae-
moglobin delta (HBD) to identify DNA copy number variations in ESCC. The primer pairs were obtained from 
Sigma-Aldrich (St Louis, MO, USA). The list of chosen primer sets are summarized in Table 5.
Real-time quantitative polymerase chain reaction (qPCR). DNA copy number changes of FAM134B 
(JK1) were determined using a rotor Gene Q real-time PCR (RT-PCR) Detection system (Qiagen). RT-PCR was 
achieved in a total volume of 10 μ l comprising 5 μ l of 2XSensiMix SYBR No-ROX master mix (Bioline, London, 
UK), 1 μ l of each 10 picomole/μ l primer, 1 μ l of cDNA/ genomic DNA at 20–50 ng/μ l and 2 μ l of Nuclease-free 
water. PCR cycling programs encompassed initial denaturation and activated the hot start DNA polymerase in 
one cycle of 7 minutes at 95 °C followed by 40 cycles of 10 seconds at 95 °C (denaturation), 30 seconds at 60 °C 
(annealing) and 20 seconds at 72 °C (extension). Melting curve analysis was carried out using 80 cycles of 30 sec-
onds increasing from 55 °C. The melting curves of all final real-time PCR products were analysed for determi-
nation of genuine products and contamination by nonspecific products and primer dimers. All samples were 
also run on 2% agarose gel electrophoresis to ensure that the correct product was amplified in the reaction. To 
increase the reliability of the results, assays were accomplished in multiple replicates and a non-template control 
was included in all the experiment. The results of the quantitative real-time polymerase change reaction were 
analysed using methods published previously29.
Figure 3. Confirmation of FAM134B (JK1) different introns sequence variant HRM curve analysis results 
via Sanger sequencing. (a) HRM curve analysis shows characteristic melting pattern of FAM134B (JK1) 
intron 2 amplicons using normalized melting curves and Sanger sequencing corroborates the mutation as 
being c. 14 + 144delA. (b) The evidence of mutant (GTG > TTG) in intron 6 of FAM134B (JK1) is shown 
using normalized melting curves and sequencing (mutant versus wild type). (c) HRM analysis shows the 
polymorphism (CAA > AAA) in intron 8 of FAM134B (JK1) as evident by normalized melting curves and 
sequencing (mutant versus wide type).
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High-Resolution Melt (HRM) curve analysis. Fifty-seven matched cancer and non-cancer tissues 
(including 18 cases with lymph node metastases) were used for HRM analysis. Sections of the lymph nodes 
were confirmed to have lymph nodes metastases by histological examination as above. HRM curve analysis was 
accomplished by amplifying target sequences on the Rotor-Gene Q detection system (Qiagen) using the software 
Rotor-Gene ScreenClust HRM Software. The exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, exon 
9 of FAM134B (JK1) were PCR amplified in a total reaction volume of 10 μ l comprising 5 μ l of 2Xsensimix HRM 
master mix, 1 μ l of 30 ng/μ l genomic DNA, diethylpyrocarbonate (DEPC, RNase free) treated water 2 μ l and 1 μ l 
of 5 μ mol/L JK-1 primer. The thermal cycling protocol started with one cycle of 98 °C for 4 minutes. Full activation 
of the SensiFAST DNA polymerase occurs within 30 seconds at 95 °C. This was followed by 40 cycles of 98 °C for 
5 seconds. Then, the reaction mix was at annealed at 60 °C for 15 seconds in exon 2, exon 5, exon 6, exon 7, exon 8, 
exon 9; 64.5 °C for 15 seconds for exon 3 and exon 4 and at 72 °C for 15 seconds for exon 1. Each PCR run included 
a negative (no template) control. The melt curve data were generated by increasing the temperature from 65 °C to 
85 °C for all assays, with a temperature increase rate of 0.05 °C/seconds and recording fluorescence at each step. 
All the reactions were done in duplicate to increase the reliability of the results. Each mutant allele had its own 
distinctive melting curve while compared to the wild-type allele. HRM results were interpreted as mutant when 
both replicates showed a variant compared to wild type. In cases of uncategorized samples, one replicate showed 
a variant and the other matched the wild type curve.
Purification of PCR products and Sanger sequencing analysis. All the possible mutations detected 
by HRM analysis were further confirmed by Sanger sequencing. After HRM curve analysis, successful and spe-
cific PCR products showing one melting peak were purified according to the manufacturer’s protocols from the 
NucleoSpin Gel and PCR Clean-up kit (Macherey- Nagel, Bethlehem, PA, USA). The purified PCR products 
were subjected to sequence by corresponding forward and reverse primer using the Big Dye Terminator (BDT) 
chemistry Version 3.1 (Applied Biosystems, Foster City, CA, USA) under standardised cycling PCR conditions 
and analysed by the Australian Genome Research Facility (AGRF) using a 3730xl Capillary sequencer (Applied 
Biosystems). The composition of DNA sequencing reactions was followed according the samples preparation 
guide from AGRF. Sequence analysis was performed with Chromas 2.31 software.
Statistical analysis. Correlations of FAM134B (JK1) copy number change and mutations with clinicopatho-
logical parameters were performed. Comparisons between groups were implemented using the chi-square test, 
likelihood ratio and Fisher’s exact test. All the data was entered into a computer data base and the statistical anal-
ysis was executed using the Statistical Package for Social Sciences for Windows (version 22.0, IBM SPSS Inc., New 
York, NY, USA). Significance level was taken at p < 0.05.
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